Profile

Cover photo
Amarantus BioScience Holdings, Inc.
39 followers|17,620 views
AboutPosts

Stream

 
Amarantus announced that the U.S. Patent and Trademark Office (USPTO) today issued U.S. Patent No. 9,066,903 entitled, "Pharmacological Treatment of Parkinson's Disease." The patent covers methods for the administration of eltoprazine, in combination with the anti-Parkinson's drug, levodopa (L-DOPA), for the treatment of Parkinson's disease. Gerald E. Commissiong, President and CEO of Amarantus stated, "We are very pleased with the issuance by the USPTO of the patent covering the use of eltoprazine in treating patients with Parkinson's disease receiving L-DOPA and who suffer from L-DOPA induced dyskinesia. This new issuance helps the Company continue to build our intellectual property estate for eltoprazine." Amarantus has initiated a multi-center, 60-subject Phase 2b study in individuals with PD-LID. The Company expects to report top-line results from this Phase 2b study in the second quarter of 2016. Read the full press release available here for additional information: http://bit.ly/1RQVQT6
1
Add a comment...
 
Results from a new study showed that college athletes are almost twice as likely to suffer serious lower body injuries in the year following a concussion. http://fxn.ws/1GqykXU
In the year following a concussion, college athletes are almost twice as likely to suffer serious lower body injuries like ankle sprains compared to the year before their head injury, according to a new study.
1
Add a comment...
 
In response to rising concern about concussions in youth football, the American Medical Association has adopted policies intended to lower the risk of these brain injuries. http://fxn.ws/1G3vmbA
The American Medical Association, responding to rising concern about concussions in youth sports like soccer and football, on Tuesday adopted policies intended to lower the risk of these brain injuries and called for prompt diagnosis and medical care.
1
Add a comment...
 
Amarantus announced today that data from the Phase 1/2a clinical study of eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID) has been accepted for presentation at the 19th International Congress of Parkinson's Disease and Movement Disorders being held June 14-18, 2015, in San Diego, CA. Professor Per Svenningsson, M.D., Ph.D., of the Centre for Molecular Medicine at Karolinska Institutet, will present poster number 331 entitled, "Single oral treatment with the 5-HT1A/B agonist, Eltoprazine, counteracts L-dopa-induced dyskinesias in Parkinson's disease: A phase I/IIA, double-blind, randomized, placebo-controlled, dose-finding study," on Monday, June 15, 2015, from 12:30-2:00 p.m. PDT. Further, poster number 331 has been selected for a guided poster tour with Professor Svenningsson. Guided Poster Tour 16 entitled, "Parkinson's Disease: Neuropharmacology," will be held at Harbor G, 2nd Level, Harbor Tower from 12:00-3:30 p.m. PDT on Thursday, June 18, 2015. Read the full press release for additional information and presentation details: http://bit.ly/1FWyjdK
1
Add a comment...
 
Amarantus completes capital restructuring in preparation for national exchange listing. Amarantus’ common stock will trade on a split-adjusted basis under a new CUSIP number and temporary ticker symbol "AMBSD” beginning on Wednesday, June 10, 2015. After 20 days, the common stock will commence trading under the ticker symbol “AMBS.” Read the full press release available here for more information: http://bit.ly/1JHGZts
1
Add a comment...
 
Amarantus announced today that the first clinical trial site is now open for enrollment for the Phase 2b study of its lead product candidate eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). The study will commence at the Parkinson's Disease and Movement Disorders Center of Boca Raton, and Stuart H. Isaacson, M.D., will serve as Principal Investigator. The multi-center, 60-subject Phase 2b study in individuals with Parkinson's disease is a double-blind, placebo-controlled, four-way crossover, dose range finding, clinical trial designed to evaluate dose response effect of repeated eltoprazine dosing on safety, tolerability and dyskinesia severity using state-of-the-art rating scales, diaries and motion sensors (ClinicalTrials.gov Identifier: NCT02439125). Pharmacokinetics and pharmacodynamics will also be evaluated. The Company anticipates that results from the study will be available in 2016. Read the full press release available here for full study details: http://bit.ly/1Jw7CRS
1
Add a comment...
Have them in circles
39 people
Jin Park's profile photo
Terry Dickenson's profile photo
One Mind's profile photo
Thomas Steele's profile photo
CHERYL JEMMOTT's profile photo
Leonardo Casini's profile photo
Laura Anthony, Esq.'s profile photo
tahir jabbar mir's profile photo
Edison Investment Research's profile photo
 
In light of recent head injuries from both Stephen Curry and Klay Thompson, National Basketball Players Association chief Michele Roberts has hired independent neurologists to study the league's "protocol" in determining what is and isn't a concussion. http://yhoo.it/1fC1MUh
NBPA chief Michele Roberts has hired neurologists to look into the NBA's handling of concussion-like symptoms.
1
Add a comment...
 
Laura Francis, a Delaware softball coach who was diagnosed with multiple sclerosis last December sat with USA Today High School Sports to share her story: http://bit.ly/1G3wjjX
1
Add a comment...
 
Alzheimer's disease is a progressive neurodegenerative disorder that results in loss of memory and other mental functions. Click here to learn 10 signs to watch for: http://lohud.us/1G3u3ta
Alzheimer's is the most common cause of dementia, a group of brain disorders that results in the loss of intellectual and social skills.
1
Add a comment...
 
Amarantus announced today that President and CEO Gerald Commissiong will be presenting Tuesday, June 16, 2015, at 2:30 p.m. ET at the BIO International Convention. Mr. Commissiong's presentation will focus on the ongoing Phase 2b clinical study for eltoprazine in Parkinson's disease levodopa-induced dyskinesia and Amarantus Diagnostics. A live webcast will be available and can be accessed on the Company's website. Click here for additional presentation information and webcast details: http://bit.ly/1JJGoau
1
Add a comment...
 
Amarantus announced two late-breaking abstracts on the LymPro Test® have been accepted for presentation at the Alzheimer’s Association International Conference® (AAIC) being held July 18-23, 2015, in Washington, DC. Amarantus Diagnostics, Inc. is a Silver Sponsor of the 2015 AAIC. Amarantus Diagnostics is a wholly-owned subsidiary of Amarantus Bioscience Holdings (OTCQB: AMBS). Click here for additional conference information and abstract details: http://bit.ly/1FGUqF3
1
Add a comment...
 
Amarantus announced today that Gerald E. Commissiong, President & CEO will be presenting at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015 at 9:00 am ET. Mr. Commissiong will provide a corporate overview and an update on the clinical development of the Company’s lead therapeutic product candidate eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). A live webcast will be available and can be accessed on the Company's website. Click here for additional presentation information and webcast details: http://bit.ly/1Kx5SJO
1
Add a comment...
People
Have them in circles
39 people
Jin Park's profile photo
Terry Dickenson's profile photo
One Mind's profile photo
Thomas Steele's profile photo
CHERYL JEMMOTT's profile photo
Leonardo Casini's profile photo
Laura Anthony, Esq.'s profile photo
tahir jabbar mir's profile photo
Edison Investment Research's profile photo
Contact Information
Contact info
Phone
(408) 737-2734
Email
Address
c/o Janssen Labs @ QB3 953 Indiana Street San Francisco, CA 94107
c/o ICS Corporate Services SA 29 quai du Mont Blanc CH-1201 Geneva Switzerland
Story
Tagline
Amarantus (OTCQB: AMBS) is a biotechnology company developing new treatments for disorders of the brain. Join us to raise awareness! #C4CT
Introduction
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) is a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis.